Drugs / Flucytosine
Flucytosine
also known as
5-FC · 5-fluorocytosine · Alcobon · Ancoban · Ancobon · Ancotil · FLC · Flourocytosine · +6 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANCOBON | — | 1971-11-26 | fda.gov ↗ |
Trials 22
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-12-14 | Denovo Biopharma LLC | Results Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine denovobiopharma.com ↗
DGM7 has been shown to be associated with response to treatment of recurrent high grade glioma (HGG) with an investigational gene therapy combination treatment, DB107, via retrospective analysis. |
| 2021-11-02 | Denovo Biopharma LLC | Results Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences denovobiopharma.com ↗
Extended benefits in patients with recurrent high grade glioma that continuously receive Toca FC after Toca 511 Treatment |
| 2021-09-16 | Transgene | Results Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002 transgene.com ↗
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002 |
| 2021-04-09 | Transgene | Results Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses transgene.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-14 | Denovo Biopharma LLC | Denovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine denovobiopharma.com ↗ |
| 2021-11-02 | Denovo Biopharma LLC | Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences denovobiopharma.com ↗ |
| 2021-09-16 | Transgene | Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002 transgene.com ↗ |
| 2021-04-09 | Transgene | Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses transgene.com ↗ |
| 2018-01-05 | Lupin Limited | Lupin launches generic Ancobon® capsules in the US lupin.com ↗ |
| 2017-07-10 | Lupin Limited | Lupin receives FDA approval for generic Ancobon® Capsules lupin.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flucytosine | “2. Flucytosine 100mg/kg/day for 14 days in divided doses” NCT06666322 ↗25“ONF is an extended-release formulation of flucytosine.” NCT06562621 ↗ “flucytosine, 5-FC, 5-FC XR, Toca FC” NCT01470794 ↗ “Oral Flucytosine (5-FC)” NCT04226066 ↗ |
| Known as | 5-FC | “The combination of amphotericin and flucytosine (5-FC) has been the mainstay of therapy for the initial management of cryptococcal meningitis for 4 decades.” NCT06666322 ↗9“Combination of amphotericin and flucytosine (5-FC) is the mainstay of therapy for the initial management of CM.” NCT06414512 ↗ “Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy” NCT00583492 ↗ “Flucytosine (5-FC, Ancotil)” NCT03724071 ↗ “Flucytosine (5-FC)” NCT01562626 ↗ “Flucytosine (5-FC)” NCT04194034 ↗ “Flucytosine (5FC)” NCT06525389 ↗ “5-FC” NCT00978107 ↗ |
| Known as | 5-fluorocytosine | “To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal...” NCT00000639 ↗ |
| Known as | Alcobon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancoban | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancobon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Ancotil | “Flucytosine (5-FC, Ancotil)” NCT03724071 ↗ |
| Known as | FLC | “fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis” NCT00000708 ↗ |
| Known as | Flourocytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Flucitosina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | flucytosine, 5-FC, 5-FC XR, Toca FC | “flucytosine, 5-FC, 5-FC XR, Toca FC” NCT01470794 ↗ |
| Known as | Flucytosinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | Fluorocytosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | NSC-103805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Known as | RO 2-9915 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1463 ↗ |
| Modality | Small molecule | — CHEMBL1463 ↗ |
| Route | Oral | “Non-AIDS patients assigned to AMB also take FLC by mouth daily.” NCT00000708 ↗ |